TSV
RXRX icon

Two Sigma Ventures’s Recursion Pharmaceuticals RXRX Stock Holding History

Two Sigma Ventures’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$9.61M Sell
903,400
-903,400
-50% -$9.15M 100% 1
2022
Q2 		$14.7M Hold
1,806,800
– – 88.76% 1
2022
Q1 		$12.9M Hold
1,806,800
– – 74.73% 1
2021
Q4 		$30.9M Buy
+1,806,800
New +$34M 61.39% 1

Other funds holding RXRX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $78.6M AUM 55.41% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OMS
Obvious Management Services San Francisco, California $42.4M AUM 54.5% 1-Year Est. Return

Two Sigma Ventures's RXRX Position: Q3 2022 in Review

Two Sigma Ventures reduced its Recursion Pharmaceuticals (RXRX) stake by 50% in Q3 2022, selling an estimated $9.15M and leaving 903,400 shares worth $9.61M. The position accounts for 100% of the portfolio, ranked #1.

Two Sigma Ventures first reported a position in RXRX in Q4 2021 and has held it in 4 quarters since. The position peaked at $30.9M in Q4 2021. 146 funds tracked by Wall St. Rank hold RXRX as of Q3 2022.

  • Two Sigma Ventures held 903,400 shares of Recursion Pharmaceuticals worth $9.61M as of Q3 2022.
  • Two Sigma Ventures sold 903,400 Recursion Pharmaceuticals shares in Q3 2022, an estimated $9.15M.
  • Recursion Pharmaceuticals made up 100% of Two Sigma Ventures's portfolio in Q3 2022, its #1 holding.
  • Two Sigma Ventures first reported a position in Recursion Pharmaceuticals in Q4 2021 and has held it in 4 quarters since.
  • Two Sigma Ventures's Recursion Pharmaceuticals position peaked at $30.9M in Q4 2021.
  • 146 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2022.

Based on Two Sigma Ventures's 13F filing for Q3 2022, filed 14 Nov 2022.